Major League Soccer Commissioner Don Garber says the league continues to look at shifting to a fall-to-spring season, saying he’d “rather get it right and take our time than get it wrong and ...

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf ...

SAN FRANCISCO, July 23, 2025 (GLOBE NEWSWIRE) -- Investors in Replimune Group, a biotechnology company focused on cancer treatments, witnessed a dramatic collapse in their holdings on July 22. Shares ...

Fintel reports that on July 23, 2025, Barclays downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 725.97% Upside As of July ...

Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...

Northern Trust Corp (NTRS) is expected to report $2.05 for 2Q. Otis Worldwide Corp (OTIS) is expected to report $0.93 for 2Q. PROG Holdings Inc (PRG) is expected to report $0.74 for 2Q. Pacific ...

Dow, Nasdaq, S&P 500 opened flat on Tuesday's US market session as investors focused on US President Donald Trump's trade ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. ("Replimune or the "Company") (NASDAQ: REPL).

Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

"REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% After FDA Response Letter -- BFA Law Announces Securities Fraud Investigation And Urges Investors To Contact The Firm >REPL" was published ...

The FDA has issued a complete response letter to Replimune indicating it is unable to approve the biologics license ...

Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...